Prellis Biologics
Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.
About Prellis Biologics
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier. The company was founded in 2016 and is based in San Francisco, California.
Company Facts
- Headquarters
- Berkeley
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- late_stage_venture
- Total Funding
- $79,372,758
- Last Funding Type
- series_c
- Last Funding Date
- 2025-03-10
- Website
- prellisbio.com
Industries & Categories
3D Printing, Biopharma, Biotechnology, Therapeutics
Social Links
Canonical: https://fsome.com/organization/prellis-biologics-42360 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.